Adaptive Biotechnologies Corporation

Informe acción NasdaqGS:ADPT

Capitalización de mercado: US$875.1m

Salud financiera de hoja de balance de Adaptive Biotechnologies

Salud financiera controles de criterios 5/6

Adaptive Biotechnologies tiene un patrimonio de los accionistas total de $223.6M y una deuda total de $132.7M, lo que sitúa su ratio deuda-patrimonio en 59.4%. Sus activos y pasivos totales son $558.5M y $334.9M respectivamente.

Información clave

59.4%

Ratio deuda-patrimonio

US$132.70m

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$243.33m
PatrimonioUS$223.57m
Total pasivoUS$334.93m
Activos totalesUS$558.51m

Actualizaciones recientes sobre salud financiera

Recent updates

Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?

Nov 01
Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?

Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 27% Higher

Oct 05
Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 27% Higher

Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk

Jul 12
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk

Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?

May 08
Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?

It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks

Apr 03
It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks

Adaptive Biotechnologies: A Post Earnings Assessment

Feb 25

Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically

Feb 17
Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically

Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%

Feb 01
Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%

Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be

Nov 17
Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be

Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Oct 13
Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Jul 06
Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding

May 05
Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding

We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely

Apr 15
We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely

Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans

Dec 13
Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans

Adaptive Biotechnologies, Epic team up to integrate clonoSEQ test in electronic record system

Oct 11

Adaptive Biotechnologies announces $250M non-dilutive royalty financing

Sep 12

We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate

Aug 14
We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate

Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth

Apr 29
Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth

Adaptive Biotechnologies: Good Buy For Long-Term Investors

Apr 15

Are Investors Undervaluing Adaptive Biotechnologies Corporation (NASDAQ:ADPT) By 22%?

Feb 26
Are Investors Undervaluing Adaptive Biotechnologies Corporation (NASDAQ:ADPT) By 22%?

We Think Adaptive Biotechnologies (NASDAQ:ADPT) Can Afford To Drive Business Growth

Jan 09
We Think Adaptive Biotechnologies (NASDAQ:ADPT) Can Afford To Drive Business Growth

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($308.3M) de ADPT superan a sus pasivos a corto plazo ($87.6M).

Pasivo a largo plazo: Los activos a corto plazo de ADPT ($308.3M) superan a sus pasivos a largo plazo ($247.3M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: ADPT tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de ADPT ha crecido de 0% a 59.4% en los últimos 5 años.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: ADPT tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: ADPT dispone de suficiente cash runway para más de 3 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 29.6% cada año


Descubre empresas con salud financiera